ПЕРОРАЛЬНЫЕ АНТИАГРЕГАНТЫ ПРИ КОРОНАРНОЙ БОЛЕЗНИ СЕРДЦА: ПОЗИЦИИ КЛОПИДОГРЕЛА

1. Bhatt DL, Fox KAA, Hacke W, et al., for the CHARISMA Investigators. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med, 2006;354:1706–1717.

2. Wang TH, Bhatt DL, Fox KAA, et al., on behalf of the CHARISMA Investigators. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J, 2007; doi:10.1093/eurheartj/ehm274.

3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996;348:1329–1339.

4. Cannon CP, on behalf of the CAPRIE Investigators Effectiveness of Clopidogrel Versus Aspirin in Preventing Acute Myocardial Infarction in Patients With Symptomatic Atherothrombosis (CAPRIE Trial). Am J Cardiol, 2002;90:760–762.

5. Bhatt DL, Hirsch AT, Ringleb PA, et al., on behalf of the CAPRIE investigators. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J, 2000;140:67–73.

6. Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation, 2001;103:363–368.

7. Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke, 2004;35:528–532.

8. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with a history of diabetes mellitus. Am J Cardiol, 2002;90:625–628.

9. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet, 2009;374:1967–1974.

10. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. Am J Cardiol, 2005;95:1218–1222.

11. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet rugs. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). CHEST, 2008;133:199S-233S.

12. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 2008;118:1894–1909.

13. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut, 2006;55:1731–1738.

14. Hansen ML, Sørensen R, Clausen MT, et al. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. Arch Intern Med, 2010;170:1433–1441.

15. Fork F-T, Lafolie P, Toth E, Lindga¨rde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol, 2000;35:464–469.

16. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol, 2006;4:860–865.

17. Bhatt DL, Flather MD, Hacke W, et al., for the CHARISMA Investigators. Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. JACC, 2007;49:1982–1982.

18. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization. Eur Heart J, 2010;31:2501–2555.

19. Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A Report of the American College of Cardiology Foundation/American Heart Association. JACC, 2011; doi:10.1016/j.jacc.2011.08.007.

20. Cassese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drugeluting stent era: a meta-analysis of randomized trials. Eur Heart J, 2012;33:3078–3087.

21. Kim B-K, Hong M-K, Shin D.-H, for the RESET Investigators. New Strategy for Discontinuation of Dual Antiplatelet Therapy. The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). JACC, 2012;60:1340–1348.

22. Valgimigli M, Campo G, Monti M, et al. Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial. Circulation, 2012; doi: CIRCULATIONAHA.111.071589.

23. Valgimigli M, Borghesi M, Tebaldi M, et al., for the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY) Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Eur Heart Journal, 2013;34:909–919.

24. Feres F, Costa RA, Abizaid A, et al.; for the OPTIMIZE Trial Investigators. Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents The OPTIMIZE Randomized Trial. JAMA, 2013; doi:10.1001/ jama.2013.282183.

25. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet, 2012;379:1393–1402.

26. Silber S, Windecker S, Vranckx P, Serruys PW, on behalf of the RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet, 2011;377:1241–1247.

27. No Stent Thrombosis Seen When Plavix and Aspirin Stopped Early New Analysis of Medtronic’s 5,000 Patient RESOLUTE Drug-Eluting Stent Clinical Program Shows No Increased Risk with Premature Cessation of Dual Antiplatelet Therapy. http://www.ptca.org/ news/2013/0314_MEDTRONIC_RESOLUTE.html.

28. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without SТ-segment elevation. N Engl J Med, 2001;345:494–502.

29. Fox KAA, Mehta SR, Peters R, et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation, 2004;110:1202–1208.

30. Mehta SR, Yusuf S, Peters RJG, et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI–CURE study. Lancet, 2001;358:527–533.

31. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med, 2005;352:1179–1189.

32. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled Trial. Lancet, 2005;366:1607–1621.

33. Явелов И. С. Двойная антитромбоцитарная терапия – проверенный временем эффективный способ лечения острого коронарного синдрома. Consilium Medicum, 2012;14 (5):46–54.

34. Dörler J, Edlinger M, Alber HF, et al.; Austrian Acute PCI Investigators. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J, 2011;32:2954–2961.

35. Koul S, Smith JG, Scherstén F, et al. Effect of upstream clopidogrel treatment in patients with STsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J, 2011;32:2989–2997.

36. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA, 2008;299:532–539.

37. Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction – a hospital registry-primary care linked cohort (MINAP– GPRD). Eur Heart J, 2011;32:2376–2386.

38. Varenhorst C, Jensevik K, Jernberg T, et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J, 2013; doi:10.1093/eurheartj/eht438.

39. Budaj A, Yusuf S, Mehta SR, et al.; for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups. Circulation, 2002;106:1622–1626.

40. Bhatt DL, Fox KAA, Hacke W, et al., for the CHARISMA Investigators. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med, 2006;354:1706–1717.

41. The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med, 2009; doi: 10.1056/NEJMoa0901301.

42. Ben-Dor I, Torguson R, Scheinowitz M, et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J, 2010;159:871–875.

43. Roy P, Bonello L, Torguson R, et al. Impact of “nuisance” bleeding on clopidogrel compliance in patients undergoing intracoronary drug eluting stent implantation. Am J Cardiol, 2008;102:1614–1617.

44. Amin AP, Bachuwar A, Reid KJ, et al. Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute Myocardial Infarction and its Impact on Health Status. JACC, 2013; doi: 10.1016/j. jacc.2013.02.044.

45. Bhatt DL, Cryer BL, Contant CF, et al., for the COGENT Investigators. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med, 2010:10.1056/NEJMoa1007964.

46. Wallentin L, Becker RC, Budaj A, et al., for the PLATO Investigators. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med, 2009;361:1045–1057.

47. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC, 2013; 61: doi:10.1016/j.jacc.2012.11.019.

48. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 2012: doi:10.1093/ eurheartj/ehs215.

49. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J, 2012; doi:10.1093/eurheartj/ehs253.

50. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012;141 (Suppl): e419S-e494S.

51. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2012; doi:10.1093/eurheartj/ehs109.

52. Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 011 ACCF/AHA/HRS Recommendations). A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2013; 127. Доступен на http://circ.ahajournals.org/content/early/2013/04/01/ CIR.0b013e318290826d.citation.

53. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) JACC, 2008;52: e1–142.

54. Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eur Heart J, 2008;29:2276–2315.

55. Mega JL, Braunwald E, Wiviott SD, et al., for the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med, 2011; doi: 10.1056/NEJMoa1112277.

56. Явелов И. С. Антитромботические препараты в профилактике тромбоэмболических осложнений после острого коронарного синдрома. Атеротромбоз, 2013;1:82–104.

57. Явелов И. С. Применение пероральных антикоагулянтов во вторичной профилактике острого коронарного синдрома: что известно к середине 2013 года. Трудный пациент, 2013;11 (7):22–31.

58. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel and vitamin K antagonists in patients with drug eluting stent implantation and an indication for oral anticoagulation. JACC, 2013, doi: 10.1016/j.jacc.2013.02.036.

59. Dewilde WJM, Oirbans T, Verheugt FWA, et al., for the WOEST study investigators Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013; http://dx.doi.org/10.1016/S0140–6736 (12)62177–1.

60. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. JACC, 2013; doi:10.1016/j. jacc.2013.05.029.

61. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome – Fact and fiction. Thromb Haemost, 2011;106:191–202.

62. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA, 2010;303:754–762.

63. Tantry US, Bonello L, Aradi D, et al., for the Working Group on On-Treatment Platelet Reactivity. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. JACC, 2013;62:2261–2273.

64. Kirtane AJ, Rinaldi M, Parise H, et al. Impact Of Point-Of-Care Platelet Function Testing Among Patients With And Without Acute Coronary Syndromes Undergoing Pci With Drug-Eluting Stents: An Adapt-Des Substudy. JACC, 2012; 59: E291.

65. Stone GW, Witzenbichler B, Weisz G, et al., for the ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPTDES): a prospective multicentre registry study. Lancet, 2013;382:614–623.

66. Reny J-L, Berdague P, Poncet A, et al., for the Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients. Results of the Antiplatelet Drug Resistances and Ischemic Events Study. Circulation, 2012;125:3201–3210.

67. Aradi D, Storey RF, Komocsi A, et al., on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J, 2013; doi:10.1093/eurheartj/eht375.

68. Gurbel PA, Erlinge D, Ohman EM, et al., for the TRILOGY ACS Platelet Function Substudy Investigators. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. The TRILOGY ACS Platelet Function Substudy. JAMA, 2012;308:1785–1794.

69. Price MJ, Berger PB, Teirstein PS, et al., for the GRAVITAS Investigators. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. The GRAVITAS Randomized Trial. JAMA, 2011;305:1097–1105.

70. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. Circulation, 2011;124:1132–1137.

71. Trenk D, Stone GW, Gawaz M, et al. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. JACC, 2012;59:2159–2164.

72. Collet J-P, Cuisset T, Rangé G, et al., for the ARCTIC Investigators. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med, 2012; DOI: 10.1056/NEJMoa1209979.